Gilead Sciences (Portugal)

Homepage: gileadpro.pt

Parent institution: Gilead Sciences (United States)

ROR: 04ek0a809

OpenAlex ID: I4405256694

Increasing HIV early diagnosis by implementing an automated screening strategy in emergency departments

2022 · Inês Vaz‐Pinto, Ana Gorgulho, et al. · HIV Medicine · 24

Assessment of the impact of the new blister packaging of Biktarvy® (B/F/TAF) on treatment satisfaction of people living with HIV

2025 · JP Cruz, O Santos, et al. · PLoS ONE · 1

Cost‐efficacy of European AIDS Clinical Society‐recommended initial antiretroviral regimens for treatment of HIV infection in Portugal

2012 · I Aldir, M Doroana, et al. · Journal of the International AIDS Society · 1

784 | Impact on Health Outcomes of Treating All Eligible Patients With Axicabtagene Ciloleucel in Portugal—a Modeling Approach

2025 · F. de Aragão, A. Carneiro, et al. · Hematological Oncology

Tenofovir Alafenamide, Emtricitabine, and Bictegravir in Switch Strategy for HIV-1 Adult Patients Due to Previous Renal Impairment Induced by Tenofovir Disoproxil Fumarate

2022 · R Correia de Abreu, C Batista, et al. · Journal of AIDS and HIV Treatment

SiNATS: Criar o Futuro

2017 · Martins, João Cristóvão · DOAJ (DOAJ: Directory of Open Access Journals)

Works count: 6

Citation count: 50